ADHD treatments can trigger psychosis

About one in 660 adolescents and young adults receiving prescription stimulants for attention deficit hyperactivity disorder (ADHD) develop new-onset psychosis, according to the New England Journal of Medicine.

The study matched 110,923 patients aged 13 to 25 years prescribed methylphenidate with the same number taking amphetamines. During a total follow-up of 143,286 person-years, there were 343 new diagnoses of psychosis associated with an antipsychotic prescription, giving an incidence of 2.4 per 1,000 person-years of stimulant exposure. The median time from the dispensing of the first stimulant to the psychotic episode was 128 days.

New use of amphetamine was associated with a higher risk of psychosis than methylphenidate: 2.83 and 1.78 episodes per 1,000 personyears of drug exposure (0.21 and 0.1 per cent of the groups respectively).

Unmeasured confounders, such as under-reported abuse of cannabis, might have contributed to the results. However, a difference in cannabis use prevalence of 61 per cent between the stimulant groups is needed to account for the findings. Moreover, the study used a “stringent” definition of psychosis.


Signs of success with MenB vaccination programme

UK leads Europe in early clinical research, but faces challenges …

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.